Document Type
Article
Publication Date
1-1-2022
Publication Title
BioImpacts : BI
Keywords
Alpha 7 nicotinic acetylcholine receptor, COVID-19, Cholinergic anti-inflammatory pathway, Vagus nerve stimulation
ISSN
2228-5652
Volume
12
Issue/No.
2
First Page
171
Last Page
174
Abstract
The cholinergic anti-inflammatory pathway (CAP) first described by Wang et al, 2003 has contemporary interest arising from the COVID-19 pandemic. While tobacco smoking has been considered an aggravating factor in the severity of COVID-19 infections, it has been suggested by some that the nicotine derived from tobacco could lessen the severity of COVID-19 infections. This spotlight briefly describes the CAP and its potential role as a therapeutic target for the treatment of COVID-19 infections using vagus nerve stimulation or selective alpha7 nicotinic acetylcholine receptor agonists.
Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
NSUWorks Citation
Mehranfard, Danial and Speth, Robert C., "Cholinergic anti-inflammatory pathway and COVID-19" (2022). HPD Articles. 41.
https://nsuworks.nova.edu/hpd_facarticles/41
ORCID ID
0000-0003-0867-2322; 0000-0002-6434-2136
DOI
10.34172/bi.2022.23980
Copyright
© 2022 The Author(s).
